113 related articles for article (PubMed ID: 4171642)
1. [The action of different forms of hormone therapy in prostatic adenoma].
Délivéliotis A; Rodis N
J Urol Nephrol (Paris); 1968 Mar; 74(3):211-22. PubMed ID: 4171642
[No Abstract] [Full Text] [Related]
2. Nonoperative management of senile prostatic hyperplasia.
Fam A
Int Surg; 1971 Oct; 56(4):252-9. PubMed ID: 4106484
[No Abstract] [Full Text] [Related]
3. Sex hormone effect upon acid phosphatase content of human seminal and prostatic fluid.
Kent JR; Suryanaryana BV; Hill M
Invest Urol; 1969 Nov; 7(3):250-6. PubMed ID: 4191423
[No Abstract] [Full Text] [Related]
4. [Therapeutic action of levorin in prostatic adenoma].
Kliucharev BV; Mikhaĭlets GA; Berman NA; Ivanov NM; Margolin AM
Urol Nefrol (Mosk); 1973; 38(3):40-3. PubMed ID: 4127896
[No Abstract] [Full Text] [Related]
5. [Conservative therapy of prostate adenoma with phenoxybenzamine. Clinical aspects and urodynamics].
Flamm J
Fortschr Med; 1981 Nov; 99(43):1820-2. PubMed ID: 6171493
[No Abstract] [Full Text] [Related]
6. [Conservative therapy of prostatic hyperplasia with urinary retention].
Djulepa J
Med Welt; 1983 Dec; 34(48):1377-9. PubMed ID: 6197601
[No Abstract] [Full Text] [Related]
7. [Hormonal treatment benign prostatic hyperplasia. A review].
Schoonees R; de Klerk JN
S Afr Med J; 1972 Sep; 46(37):1337-9. PubMed ID: 4118059
[No Abstract] [Full Text] [Related]
8. Cytotoxic drug and hormone therapy after adrenalectomy for advanced breast cancer.
Keating JL; Yonemoto RH; Byron RL
Surg Gynecol Obstet; 1968 Sep; 127(3):538-42. PubMed ID: 4969618
[No Abstract] [Full Text] [Related]
9. [On the efficacy of conjugated estrogens in therapy of bladder retention due to prostatic hypertrophy].
Giannoni R; Zini S
Friuli Med; 1964; 19(6):1033-47. PubMed ID: 4157594
[No Abstract] [Full Text] [Related]
10. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
Crawford ED
BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729
[No Abstract] [Full Text] [Related]
11. [Hormone therapy for prostatic carcinoma and hypertrophy].
Hanschke HJ
Dtsch Med Wochenschr; 1969 Mar; 94(13):677-8. PubMed ID: 4180637
[No Abstract] [Full Text] [Related]
12. [The objective of medical treatment: relieve the symptoms or stop the course?].
Desgrandchamps F
Ann Urol (Paris); 2006 Mar; 40 Spec No 1():14-6. PubMed ID: 16649585
[No Abstract] [Full Text] [Related]
13. [Gestonorone therapy of prostatic adenoma].
Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough treatment for prostate enlargement.
Johns Hopkins Med Lett Health After 50; 2003 Apr; 15(2):3, 7. PubMed ID: 12712965
[No Abstract] [Full Text] [Related]
15. [Current possibilities in the treatment of prostatic adenoma].
Grims P; Bemarić R
Lijec Vjesn; 1974 Dec; 96(12):B786-9. PubMed ID: 4142059
[No Abstract] [Full Text] [Related]
16. [Drug therapy in patients with adenoma of the prostate gland with urination disorders].
Spivak LG; Vinarov AZ; Evdokimov MS
Urologiia; 2012; (6):96-9. PubMed ID: 23379250
[No Abstract] [Full Text] [Related]
17. Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Armitage JN; Emberton M
BJU Int; 2006 Mar; 97(3):439-41. PubMed ID: 16469003
[No Abstract] [Full Text] [Related]
18. [Treatment of urination disorders with Raveron].
Ichim V
Z Urol Nephrol; 1970 Apr; 63(4):255-60. PubMed ID: 4109019
[No Abstract] [Full Text] [Related]
19. [Urination disorders caused by prostatic hyperplasia. Effect of Bazoton, Harzol and Prosta-capsules].
Hallwachs O
MMW Munch Med Wochenschr; 1981 Oct; 123(44):1675-6. PubMed ID: 6171728
[No Abstract] [Full Text] [Related]
20. Androgen replacement and/or 5 alpha reductase inhibitors in aging men.
Klotz LH
Can J Urol; 2006 Feb; 13 Suppl 1():44-5. PubMed ID: 16526981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
